secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-10-15T14:27:48+00:00
Accession:  0001193125-26-422437
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Corbus Pharmaceuticals updates investor presentation; no new financial or clinical data disclosed
--------------------------------------------------------------------------------

- Exhibit 99.1 is an updated corporate deck titled 'Connecting Innovation to Purpose,' dated October 15, 2026.
- The filing text discloses no financial results, trial data, guidance or deal terms, and no substantive content from the deck was included.
- Signed by CEO Yuval Cohen; Corbus (CRBP) common stock is listed on the Nasdaq Capital Market.
- Company headquarters listed as 500 River Ridge Drive, Norwood, Massachusetts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/0001193125-26-422437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-422437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer